Research programme: LADD immunotherapeutics - Aduro BioTech

Drug Profile

Research programme: LADD immunotherapeutics - Aduro BioTech

Alternative Names: Cancer vaccines - Aduro BioTech; Infectious disease vaccines - Aduro BioTech; KBMA Ba; KBMA vaccines; LADD vaccines; Lm Ft; Lm HBV; Lm HIV; Lm Malaria; Lm Melanoma; Lm Prostate; personalized LADD immunotherapy; pLADD

Latest Information Update: 28 Jan 2017

Price : $50

At a glance

  • Originator Cerus Corporation
  • Developer Aduro BioTech
  • Class Bacterial vaccines; Cancer vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Prostate cancer
  • No development reported Anthrax; Hepatitis B; HIV infections; Malaria; Malignant melanoma; Tularaemia

Most Recent Events

  • 19 Jan 2017 US FDA approves IND application for personalised LADD in Gastrointestinal cancer
  • 09 Nov 2016 Aduro Biotech files an IND application with the US FDA in for Gastrointestinal cancer
  • 05 Jan 2016 Aduro BioTech receives patent allowance for its LADD platform in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top